Stuart Chaussee & Associates, Inc. Astrazeneca PLC Transaction History
Stuart Chaussee & Associates, Inc.
- $268 Million
- Q3 2025
A detailed history of Stuart Chaussee & Associates, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Stuart Chaussee & Associates, Inc. holds 165 shares of AZN stock, worth $13,586. This represents 0.0% of its overall portfolio holdings.
Number of Shares
165
Previous 165
-0.0%
Holding current value
$13,586
Previous $11,000
9.09%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AZN
# of Institutions
1,451Shares Held
489MCall Options Held
7.22MPut Options Held
2.57M-
Price T Rowe Associates Inc Baltimore, MD51.9MShares$4.28 Billion0.41% of portfolio
-
Primecap Management CO Pasadena, CA41.2MShares$3.39 Billion2.35% of portfolio
-
Wellington Management Group LLP Boston, MA34.3MShares$2.83 Billion0.45% of portfolio
-
Capital International Investors Los Angeles, CA31.4MShares$2.59 Billion0.39% of portfolio
-
Bank Of America Corp Charlotte, NC31.2MShares$2.57 Billion0.16% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $255B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...